Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Average PT from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $19.71.

A number of research analysts have weighed in on ALT shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, November 14th. Stifel Nicolaus assumed coverage on shares of Altimmune in a report on Wednesday. They set a “buy” rating and a $18.00 target price on the stock. Finally, UBS Group began coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock.

Institutional Trading of Altimmune

Several large investors have recently added to or reduced their stakes in ALT. Dimensional Fund Advisors LP boosted its holdings in shares of Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after purchasing an additional 335,444 shares during the period. Bellevue Group AG lifted its position in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after buying an additional 263,660 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Altimmune during the 3rd quarter valued at $674,000. Los Angeles Capital Management LLC acquired a new position in shares of Altimmune in the second quarter worth $689,000. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Altimmune by 74.4% during the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after acquiring an additional 92,498 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Stock Performance

ALT opened at $7.45 on Tuesday. The stock has a market capitalization of $529.88 million, a PE ratio of -4.81 and a beta of 0.22. Altimmune has a 1 year low of $5.28 and a 1 year high of $14.84. The company’s 50 day simple moving average is $8.10 and its 200 day simple moving average is $7.20.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter in the previous year, the company earned ($0.39) earnings per share. As a group, sell-side analysts expect that Altimmune will post -1.36 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.